Del Val A, Ponce J, Talens A, Martí-Bonmati L, Garrigues V, Berenguer J
Servicio de Medicina Digestiva, Hospital La Fe, Valencia.
Rev Esp Enferm Dig. 1991 Mar;79(3):215-7.
A patient with carcinoid syndrome was treated with the somatostatin analogue (SMS 201-995). The drug significantly improved the symptoms of the patient, flushing and diarrhea, and reduced urinary excretion of 5-hydroxyindole acetic acid. However, hepatic metastases remained unchanged. Clinical or biochemical adverse effects were not present during the treatment period.
一名类癌综合征患者接受了生长抑素类似物(SMS 201-995)治疗。该药物显著改善了患者的潮红和腹泻症状,并减少了5-羟吲哚乙酸的尿排泄量。然而,肝转移灶保持不变。治疗期间未出现临床或生化不良反应。